Former VP, Oncology, from Pfizer and Otsuka Joins Accelovance to Augment Oncology Growth
PR Newswire
ROCKVILLE, Md., Sept. 30, 2014
ROCKVILLE, Md., Sept. 30, 2014 /PRNewswire-USNewswire/ -- Accelovance, Inc. (Accelovance), a contract research organization (CRO) focusing in early phase oncology, vaccines, and general medicine, today announced that Dr. Joseph D. Purvis has joined the company as Vice President Medical Affairs, Oncology.
Accelovance Logo
"I'm excited to announce Dr. Purvis' addition to our company, his expertise will be invaluable as we continue our growth within early phase oncology," said Stephen Trevisan, Accelovance's President and CEO. "Joe joins Accelovance with an impressive depth and breadth of experience in oncology drug development which he will apply to progress the development goals of our oncology clients."
Dr. Purvis brings more than 25 years of oncology drug development experience to Accelovance, having provided significant contribution in the development, approval, and postmarketing development of multiple cytotoxic, biological, targeted, and hormonal products; including: IV Alkeran®, IV Zyloprim®, Navelbine®, Eloxatin®, Nolvadex®, Faslodex®, Arimidex®, Casodex®, Iressa®, and Torisel®. He has extensive regulatory experience, especially with the FDA and EMA, and has worked with community and academic oncologists and oncology cooperative groups. He has played a leadership role in Development and Medical Affairs groups at both small and large pharmaceutical companies, including Cell Pathways, AstraZeneca, Wyeth/Pfizer Pharmaceuticals, and Otsuka Pharmaceuticals.
Dr. Purvis is an alumnus of Haverford College and of Jefferson Medical College. Following his training in Internal Medicine at Hartford Hospital and in Medical Oncology at the Mayo Clinic, he was an Attending Physician in Hematology and Medical Oncology at the Cleveland Clinic, where he was co-Chairman of several tumor specific clinics. Dr. Purvis has also served as Clinical Assistant Professor in Medical Oncology and co-Chairman of the Brain Tumor Clinic at the University of North Carolina, Chapel Hill.
Dr. Purvis will be based in Accelovance's Raleigh Durham, NC office.
About Accelovance
Accelovance, Inc., headquartered in Rockville, MD, is an award-winning Contract Research Organization (CRO) focused primarily in early phase oncology, vaccines, and general medicine. As a clinical services provider to the pharmaceutical and biotechnology industries, Accelovance offers comprehensive clinical development services including management and implementation of Phase I-IV clinical trials and a Clinical Call Center used for recruitment, post-marketing surveillance, and long-term survival follow-up. For more information, visit the company's Web site at www.accelovance.com.
Press Contact: Michael Keens, VP Business Development
240.238.4941
[email protected]
Twitter: @Accelovance
Logo - http://photos.prnewswire.com/prnh/20140219/DC68221LOGO
SOURCE Accelovance